Chan Linda, Yu Esther Yee Tak, Wan Eric Yuk Fai, Wong Samuel Yeung Shan, Chao David Vai Kiong, Ko Welchie Wai Kit, Chen Catherine Xiao Rui, Chan Paul Po Ling, Bilney Emma Victoria Marianne, Lee Eng Sing, Ng Wei Leik, Lam Cindy Lo Kuen
Department of Family Medicine and Primary Care, Ap Lei Chau Clinic, The University of Hong Kong, 3/F, 161 Main Street, Ap Lei Chau, Hong Kong SAR, China.
The Bau Institute of Medical and Health Sciences Education, The University of Hong Kong, Hong Kong SAR, China.
BMC Med. 2025 Mar 31;23(1):190. doi: 10.1186/s12916-025-04007-z.
Delayed diagnosis and treatment of type 2 diabetes increases diabetes-related complications, making the high prevalence of undiagnosed type 2 diabetes in Hong Kong an important concern. Point-of-care capillary HbA1c (POC-cHbA1c) testing holds promise as a comparably accurate, convenient, and timely alternative to venous HbA1c (vHbA1c) for type 2 diabetes screening, yet randomized trials are lacking. This study compared the effectiveness of a 2-step active opportunistic screening strategy using POC-cHbA1c versus usual practice employing vHbA1c and multiple clinic visits in detecting type 2 diabetes among at-risk primary care patients. The primary outcomes were to identify the difference in the proportion of type 2 diabetes detected between intervention (POC-cHbA1c) and control (vHbA1c) groups and the uptake rate of POC-cHbA1c versus vHbA1c testing among consenting participants.
A cluster randomized controlled trial was conducted in 8 General Out-Patient Clinics between June 2022 and January 2024 using 2-step active opportunistic screening. In step 1, risk factor count, 852 at-risk patients were identified through consecutive sampling during their primary care consultation by specific inclusion and exclusion criteria. In step 2, these at-risk patients then underwent POC-cHbA1c (intervention) or vHbA1c (control) testing. If preliminary HbA1c was ≥ 5.6%, a confirmatory oral glucose tolerance test was offered. Randomization occurred at the clinic level using a random allocation sequence generated by statistical software. Multilevel logistic regression analyses were employed to evaluate the effect of the intervention on the uptake rate, adjusting for patient characteristics and clinic clustering.
POC-cHbA1c had a higher uptake rate than vHbA1c (76.0% vs 37.5%; OR = 7.06, 95% CI [2.47-20.18], p < 0.001). A greater proportion of type 2 diabetes (4.2% vs 1.4%; p = 0.016) and pre-diabetes (11.8% vs 6.9%; p = 0.015) were detected using POC-cHbA1c versus vHbA1c. POC-cHbA1c was more likely to detect type 2 diabetes/pre-diabetes combined (OR = 1.99, 95% CI [1.01-3.95], p = 0.048). The number-needed-to-screen to detect one additional type 2 diabetes patient with POC-cHbA1c was 61 versus vHbA1c.
POC-cHbA1c testing was associated with a higher uptake rate and detection of type 2 diabetes versus vHbA1c, underscoring its potential as an effective type 2 diabetes screening strategy in primary care.
NCT06382363 (retrospectively registered: 2024-04-19).
2型糖尿病的延迟诊断和治疗会增加糖尿病相关并发症,香港未确诊2型糖尿病的高患病率成为一个重要问题。即时检测毛细血管糖化血红蛋白(POC-cHbA1c)有望成为一种相对准确、便捷且及时的替代方法,用于2型糖尿病筛查,以取代静脉糖化血红蛋白(vHbA1c)检测,但目前缺乏随机试验。本研究比较了采用POC-cHbA1c的两步主动机会性筛查策略与采用vHbA1c及多次门诊就诊的常规做法在高危基层医疗患者中检测2型糖尿病的有效性。主要结局是确定干预组(POC-cHbA1c)和对照组(vHbA1c)之间检测出的2型糖尿病比例差异,以及在同意参与的参与者中POC-cHbA1c与vHbA1c检测的接受率。
2022年6月至2024年1月期间,在8家普通门诊诊所进行了一项整群随机对照试验,采用两步主动机会性筛查。在第一步中,通过特定的纳入和排除标准,在基层医疗咨询期间连续抽样,确定了852名高危患者。在第二步中,这些高危患者随后接受了POC-cHbA1c(干预组)或vHbA1c(对照组)检测。如果初步糖化血红蛋白≥5.6%,则提供确诊的口服葡萄糖耐量试验。使用统计软件生成的随机分配序列在诊所层面进行随机分组。采用多水平逻辑回归分析来评估干预对接受率的影响,并对患者特征和诊所聚类进行调整。
POC-cHbA1c的接受率高于vHbA1c(76.0%对37.5%;OR = 7.06,95%CI [2.47 - 20.18],p < 0.001)。与vHbA1c相比,使用POC-cHbA1c检测出的2型糖尿病(4.2%对1.4%;p = 0.016)和糖尿病前期(11.8%对6.9%;p = 0.015)比例更高。POC-cHbA1c更有可能检测出合并的2型糖尿病/糖尿病前期(OR = 1.99,95%CI [1.01 - 3.95],p =